Using a Treat-to-Target Management Strategy to Improve the Doctor-Patient Relationship in Inflammatory Bowel Disease

American Journal of Gastroenterology

Volumn 110, Issue 9, 2015, Pages 1252-1256

  Rubin, David T ^a,b   Cleveland, Noa Krugliak ^a,c  

^a UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CLINICAL ASSESSMENT; CLINICAL EFFECTIVENESS; CLINICAL PRACTICE; CLINICAL TRIAL (TOPIC); DISEASE ACTIVITY; DISEASE CONTROL; DOCTOR PATIENT RELATION; EVIDENCE BASED PRACTICE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HUMAN; INFLAMMATORY BOWEL DISEASE; MANAGED CARE; MEDICAL DECISION MAKING; MEDICAL INFORMATION; NUTRIENT AVAILABILITY; OUTCOME ASSESSMENT; PATIENT AUTONOMY; PATIENT CARE; PATIENT COMPLIANCE; PATIENT MONITORING; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SELF CARE; TREAT TO TARGET MANAGEMENT; TREATMENT INDICATION; TREATMENT REFUSAL; TRUST; DISEASE MANAGEMENT; INFLAMMATORY BOWEL DISEASES; PRACTICE GUIDELINE;

DISEASE MANAGEMENT; HUMANS; INFLAMMATORY BOWEL DISEASES; PHYSICIAN-PATIENT RELATIONS; PRACTICE GUIDELINES AS TOPIC;

EID: 84941260343     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2015.86     Document Type: Article

References (13)

1. Siegel CA. Shared decision making in infl ammatory bowel disease: helping patients understand the tradeoff s between treatment options. Gut 2012; 61: 459-65.
2. Siegel CA. Review article: explaining risks of infl ammatory bowel disease therapy to patients. Aliment Pharmacol Th er 2011; 33: 23-32.
3. Hayward RA, Asch SM, Hogan MM et al. Sins of omission: getting too little medical care may be the greatest threat to patient safety. J Gen Intern Med 2005; 20: 686-91.
4. Levesque BG, Sandborn WJ, Ruel J et al. Converging goals of treatment for infl ammatory bowel disease, from clinical trials and practice. Gastroenterology 2015; 148: 37-51. e1.
5. Mazzuoli S, Guglielmi FW, Antonelli E et al. Defi nition and evaluation of mucosal healing in clinical practice. Dig Liver Dis 2013; 45: 969-77.
6. Dave M, Loftus EV Jr. Mucosal healing in infl ammatory bowel disease-a true paradigm of success? Gastroenterol Hepatol (NY) 2012; 8: 29-38.
7. Bryant RV, Winer S, Spl T et al. Systematic review: histological remission in infl ammatory bowel disease. Is 'complete' remission the new treatment paradigm? An IOIBD initiative. J Crohns Colitis 2014; 8: 1582-97.
8. Ghosh S, D'Haens G, Feagan BG et al. What do changes in infl ammatory bowel disease management mean for our patients? J Crohns Colitis 2012; 6: S243-9.
9. Fraenkel L, Seng EK, Cunningham M et al. Understanding how patients (vs physicians) approach the decision to escalate treatment: a proposed conceptual model. Rheumatology (Oxford) 2015; 54: 278-85.
10. Smolen JS, Aletaha D, Bijlsma JW et al. T2T Expert Committee. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010; 69: 631-7.
11. Trial of a Treatment Algorithm for the Management of Crohn's Disease (REACT). https://clinicaltrials. gov/show/NCT01030809. Last accessed 3 February 2015.
12. Hibbard JH, Mahoney ER, Stock R et al. Do increases in patient activation result in improved self-management behaviors? Health Serv Res 2007; 42: 1443-63.
13. Fisher R, William U, Bruce P. Don't bargain over positions. In: Getting to Yes: Negotiating an Agreement without Giving in. Random House Business: London, 2012, pp 3-15.